v3.26.1
GOODWILL AND INTANGIBLE ASSETS (Details Narrative)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
Jul. 25, 2024
USD ($)
Intangible Asset, Finite-Lived [Line Items]            
Intangible assets, net $ 70,065,371 $ 70,065,371   $ 70,973,064 $ 76,400,000  
Fair value of product technologies income approach description   Key assumptions include a 2% long-term revenue growth rate and 3% contributory asset charge rate. The Company discounted the expected future cash flows at a 53.0% rate of return, equal to the weighted-average cost of capital plus 10%, to reflect the risk of the cash flows related to the product technologies.        
Goodwill impaired method for fair value discerption   The fair value of each product technology was determined using the MPEEM, an income approach that isolates the cash flows attributable solely to the subject intangible asset by projecting revenues and operating costs, deducting contributory asset charges (working capital at 4.0%, property and equipment at 12.9%), and discounting the resulting excess earnings to present value using risk-adjusted discount rates. A tax amortization benefit is included in each fair value indication. Projections reflect each asset’s market size, projected penetration, and net pricing assumptions, with a long-term growth rate of 4.8% applied at terminal value, benchmarked to long-term U.S. nominal GDP expectations. Key valuation inputs included: a risk-free rate of 4.79% (20-year U.S. Treasury yield as of December 31, 2025); a market rate of return of 13.0% (10-year CAGR of S&P 500, 2016–2025); an unlevered beta of 0.98 (Damodaran pharmaceutical industry data); and an effective tax rate of 26.7% (combined U.S. federal rate of 21% and New York state rate of 7.3%).        
Shares | shares       40,630,815    
Impairment of intangible assets       $ 20,700,000    
Carrying amount of goodwill of reporting unit       82,700,000    
Decrease in carrying amount of goodwill of reporting unit       62,000,000.0    
Goodwill impairmrnt       21,372,960    
Goodwill impaired method for fair value discerption   The Company performs its annual impairment test of indefinite-lived IPR&D assets as of December 31 each year, and on an interim basis when triggering events are identified. The fair value of each IPR&D asset was estimated using MPEEM, as described above. The required return on asset applied to SCN-104, SCN-106, and SCN-107 was 49.9%, reflecting a base unlevered cost of capital of 12.9% plus a 37.0% development and commercialization risk premium to capture regulatory approval uncertainty, market adoption risk, and execution risk associated with pre-commercial pharmaceutical assets. Based on the annual impairment test, the carrying amounts of SCN-104, SCN-106, and SCN-107 exceeded their respective estimated fair values as of December 31, 2025. In accordance with ASC 350-30-35, each asset was written down to its estimated fair value.        
Estimated useful life 13 years 13 years        
Amortization of intangible assets   $ 907,693      
Goodwill $ 22,238,461 22,238,461        
Undiscounted future cash flows   71,100,000        
Undiscounted future cash flows carrying amount   23,100,000        
Difference in undiscounted future cash flows and carrying amount   $ 48,000,000.0        
SCN-102 [Member]            
Intangible Asset, Finite-Lived [Line Items]            
Estimated useful life 13 years 13 years        
Amortization of intangible assets $ 453,846 $ 907,693   453,846    
Estimated future annual amortization expense   1,815,385        
SCN-107 [Member]            
Intangible Asset, Finite-Lived [Line Items]            
Impairment charges       $ 4,973,090    
Measurement Input, Share Price [Member]            
Intangible Asset, Finite-Lived [Line Items]            
Share price       0.51    
Scienture Inc [Member]            
Intangible Asset, Finite-Lived [Line Items]            
Goodwill           $ 21,372,960
Intangible assets, net $ 76,400,000 $ 76,400,000       $ 76,400,000